+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

China In Vitro Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 70 Pages
  • August 2022
  • Region: China
  • Mordor Intelligence
  • ID: 5318506
The Chinese in vitro diagnostics market is projected to register a CAGR of 6.6% during the forecast period.

In vitro diagnostics (IVDs) play an important role in detecting infectious diseases. A large number of molecular assays and immunoassays are being used for the detection of COVID-19. China represents one of the largest in vitro diagnostics markets in the Asia-Pacific region, and this trend is expected to continue over the forecast period. Due to an increase in the geriatric population and the high burden of chronic and infectious diseases, like diabetes, cancer, and COVID-19, the market studied is slated to show significant growth, as these chronic disorders can be diagnosed and monitored using in vitro diagnostics (IVD) products.

According to the World Health Organization (WHO), 102,762 COVID-19 cases were recorded as of March 2021, with 4,851 deaths in China. The increasing burden of the COVID-19 pandemic will lead to a high requirement of tests, which is expected to boost the IVD market in the country.

The State Council issued a guideline to implement the country's Healthy China initiative to diminish the incidence of disability among elderly people aged between 65 and 74 years by 2022 by offering medical and health services. Such initiatives by the government are expected to boost market growth during the forecast period. However, a lack of proper reimbursement and stringent regulatory framework might hamper the market’s growth.

Key Market Trends

Molecular Diagnostics Segment Dominates the Chinese In Vitro Diagnostics Market

In diagnostics research, one of the most valuable advancements has been in the form of molecular diagnostic tools. The polymerase chain reaction is the most established forefront of molecular diagnostics. The real-time PCR products simultaneously detect viruses, bacteria, fungi, and parasites, allowing molecular laboratories to operate at lower costs and ensure better outcomes.

Molecular diagnostic tests are used to detect specific sequences in DNA or RNA (including single nucleotide polymorphism (SNP), deletions, rearrangements, insertions, and others) that may or may not be associated with any disease.

Molecular diagnostics are mainly used to diagnose infectious diseases, and with the rising burden and increasing spread of the COVID-19 pandemic, the segment is at its peak in the country. Molecular diagnostic assays are required to detect viral RNAs that are very specific to the SARS-CoV-2 virus, which causes COVID-19.

In addition, the rising burden of infectious disease can be attributed to the segment’s growth. For instance, according to the National Health Commission, nearly 1.71 million cases of infectious diseases were reported on the mainland for December 2019. Approximately 288,739 cases were classified as Class B infectious diseases. Viral hepatitis, tuberculosis (TB), syphilis, scarlet fever, and gonorrhea accounted for 94% of these cases. Thus, owing to the rising importance given by clinical laboratories to diagnose diseases in the early stage of development, collaboration with domestic manufacturers, and new product launches, the molecular diagnostics segment is expected to witness good growth over the forecast period in China.

Competitive Landscape

Many players in this market are trying to expand their product portfolio in order to increase their global market share. These companies focus on strategies, such as mergers and acquisitions, collaborations, and new product developments. In March 2021, OpGen announced that it had received regulatory approval from the Chinese National Medical Products Administration for its Curetis Unyvero system as an in vitro diagnostics instrument system. This submission was filed in 2019 and included the Unyvero A50 Analyzer, the Unyvero L4 Lysator, and the Unyvero C8 Cockpit. These factors are expected to propel market growth. Key players in the Chinese in vitro diagnostics market are Abbott Laboratories, Shanghai Kehua Bio-Engineering Co. Ltd, Autobio Diagnostics Co., Mindray Medical International Limited, and Maccura Biotechnology, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Burden of Chronic Diseases and Infectious Diseases
4.2.2 Increasing Use of Point-of-Care (POC) Diagnostics Spurring the IVD Market
4.2.3 Increasing Awareness and Acceptance of Personalized Medicine
4.3 Market Restraints
4.3.1 Lack of Proper Reimbursement
4.3.2 Stringent Regulatory Framework
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Test Type
5.1.1 Clinical Chemistry
5.1.2 Molecular Diagnostics
5.1.3 Immunodiagnostics
5.1.4 Hematology
5.1.5 Other Types
5.2 By Product
5.2.1 Instrument
5.2.2 Reagent
5.2.3 Other Products
5.3 By Usability
5.3.1 Disposable IVD Devices
5.3.2 Reusable IVD Devices
5.4 By Application
5.4.1 Infectious Disease
5.4.2 Diabetes
5.4.3 Cancer/Oncology
5.4.4 Cardiology
5.4.5 Autoimmune Disease
5.4.6 Nephrology
5.4.7 Other Applications
5.5 By End User
5.5.1 Diagnostic Laboratories
5.5.2 Hospitals and Clinics
5.5.3 Other End Users
6.1 Company Profiles
6.1.1 Autobio Diagnostics Co.
6.1.2 F. Hoffmann-La Roche AG
6.1.3 Becton Dickinson & Company
6.1.4 Shanghai Kehua Bio-Engineering Co. Ltd
6.1.5 Abbott Laboratories
6.1.6 Thermofisher Scientific Inc.
6.1.8 Xiamen Boson Biotech Co. Ltd
6.1.9 Maccura Biotechnology Co. Ltd
6.1.10 BGI Group
6.1.11 BioMerieux SA
6.1.12 Bio-Rad Laboratories Inc.
6.1.13 Danaher Corporation
6.1.14 Arkray Inc.
6.1.15 Mindray Medical International Limited

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Autobio Diagnostics Co.
  • F. Hoffmann-La Roche AG
  • Becton Dickinson & Company
  • Shanghai Kehua Bio-Engineering Co. Ltd
  • Abbott Laboratories
  • Thermofisher Scientific Inc.
  • Xiamen Boson Biotech Co. Ltd
  • Maccura Biotechnology Co. Ltd
  • BGI Group
  • BioMerieux SA
  • Bio-Rad Laboratories Inc.
  • Danaher Corporation
  • Arkray Inc.
  • Mindray Medical International Limited